NZ227032A - Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom - Google Patents

Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom

Info

Publication number
NZ227032A
NZ227032A NZ227032A NZ22703288A NZ227032A NZ 227032 A NZ227032 A NZ 227032A NZ 227032 A NZ227032 A NZ 227032A NZ 22703288 A NZ22703288 A NZ 22703288A NZ 227032 A NZ227032 A NZ 227032A
Authority
NZ
New Zealand
Prior art keywords
formula
active substance
ramipril
formulation
pharmaceutically acceptable
Prior art date
Application number
NZ227032A
Other languages
English (en)
Inventor
Werner Fulberth
Richard Leeb
Manfred Radau
Willi Stammberger
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NZ227032A publication Critical patent/NZ227032A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
    • C08G59/40—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the curing agents used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ227032A 1987-11-24 1988-11-22 Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom NZ227032A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873739690 DE3739690A1 (de) 1987-11-24 1987-11-24 Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen

Publications (1)

Publication Number Publication Date
NZ227032A true NZ227032A (en) 1991-05-28

Family

ID=6341084

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ227032A NZ227032A (en) 1987-11-24 1988-11-22 Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom

Country Status (21)

Country Link
US (2) US5151433A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0317878B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0768140B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970004908B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1028962C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE74513T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU615495B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1338344C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3739690A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK168423B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2033400T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI93693C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004925T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU202100B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61173B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL88460A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO176550C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ227032A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH27416A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT89061B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA888734B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
SK283370B6 (sk) * 1995-12-27 2003-06-03 Janssen Pharmaceutica N. V. Bioadhezívna farmaceutická kompozícia a spôsob jej prípravy
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
CA2357982A1 (en) * 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
AU2003201071A1 (en) * 2002-01-15 2003-07-30 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
EP1653929A1 (en) * 2003-01-22 2006-05-10 Sandoz AG Solid pharmaceutical composition comprising ramipril
GB0301471D0 (en) * 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
US20050069586A1 (en) * 2003-06-26 2005-03-31 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
WO2005041940A1 (en) * 2003-10-30 2005-05-12 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
US20060159742A1 (en) * 2004-11-05 2006-07-20 King Pharmaceutical Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
KR100679166B1 (ko) 2005-10-04 2007-02-06 신풍제약주식회사 안정성이 증진된 약제학적 조성물 및 그의 제조방법
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
CA2646066A1 (en) * 2006-03-28 2007-10-04 Gelesis, Inc. Use of polymeric materials with other substances for improved performance
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
JP2009533461A (ja) * 2006-04-19 2009-09-17 テバ ファーマシューティカル インダストリーズ リミティド ２−アザ−ビシクロ［３．３．０］−オクタン−３−カルボン酸誘導体の安定な医薬組成物
US20070281000A1 (en) * 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
EP1864677B1 (en) * 2006-06-02 2008-01-02 Teva Pharmaceutical Industries Ltd Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof
CA2652620A1 (en) * 2006-06-02 2007-12-13 Teva Pharmaceutical Industries Ltd. Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
CA2653382A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
JP2010501604A (ja) * 2006-08-28 2010-01-21 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング グルコースレベルを低下させる方法
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
PL382311A1 (pl) * 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
EP2273985B1 (en) 2008-03-28 2016-02-17 Ferrer Internacional, S.A. Capsule for the prevention of cardiovascular diseases
WO2010030735A2 (en) * 2008-09-11 2010-03-18 Aethos Pharmaceuticals, Inc. Stabilized coating for pharmaceutical formulations
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
BR112014020184B1 (pt) 2012-02-17 2021-11-30 Egis Gyógyszergyár Zrt Preparação farmacêutica que contém anlodipina e ra-mipril
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
TWI668285B (zh) * 2015-12-31 2019-08-11 長興材料工業股份有限公司 可熱聚合之組合物、由此形成之組成液及其用途
EP3275432A1 (en) 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Dosage form with ace inhibitor
EP4106733A2 (en) 2020-02-10 2022-12-28 Adamed Pharma S.A. Stable ramipril composition and fixed dose composition comprising thereof
CN115068434B (zh) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
DE3039073A1 (de) * 1980-10-16 1982-05-19 Röhm GmbH, 6100 Darmstadt Umhuelltes acetylsalicylsaeurepraeparat
ATE20469T1 (de) * 1980-10-23 1986-07-15 Schering Corp Carboxyalkyl-dipeptide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
AU4104085A (en) * 1984-04-13 1985-10-17 Macewans Machinery Ltd. Steam-heated beater
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
DE3610391A1 (de) * 1986-03-27 1987-10-08 Hoechst Ag Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system

Also Published As

Publication number Publication date
DE3739690A1 (de) 1989-06-08
FI885398A0 (fi) 1988-11-22
IE883505L (en) 1989-05-24
KR890007739A (ko) 1989-07-05
EP0317878B1 (de) 1992-04-08
GR3004925T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-04-28
NO885213D0 (no) 1988-11-23
ZA888734B (en) 1989-07-26
IE61173B1 (en) 1994-10-05
AU615495B2 (en) 1991-10-03
ATE74513T1 (de) 1992-04-15
NO176550C (no) 1995-04-26
PT89061B (pt) 1993-03-31
US5442008A (en) 1995-08-15
HU202100B (en) 1991-02-28
IL88460A0 (en) 1989-06-30
PH27416A (en) 1993-06-21
PT89061A (pt) 1988-12-01
DK168423B1 (da) 1994-03-28
NO885213L (no) 1989-05-25
DE3869919D1 (de) 1992-05-14
HUT48455A (en) 1989-06-28
CA1338344C (en) 1996-05-21
FI93693B (fi) 1995-02-15
CN1042917A (zh) 1990-06-13
NO176550B (no) 1995-01-16
ES2033400T3 (es) 1993-03-16
JPH0768140B2 (ja) 1995-07-26
AU2581888A (en) 1989-05-25
FI93693C (fi) 1995-05-26
JPH01165596A (ja) 1989-06-29
CN1028962C (zh) 1995-06-21
US5151433A (en) 1992-09-29
DK653688A (da) 1989-05-25
DK653688D0 (da) 1988-11-23
FI885398A7 (fi) 1989-05-25
EP0317878A1 (de) 1989-05-31
KR970004908B1 (ko) 1997-04-08

Similar Documents

Publication Publication Date Title
NZ227032A (en) Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom
US5049394A (en) Pharmaceutical composition containing high drug load and method for preparing same
KR100348842B1 (ko) 염기성물질로안정화된약제학적조성물
IL104041A (en) Pharmaceutical compositions comprising an hmg-CoA reductase inhibitor compound and method for their preparation
EA002331B1 (ru) Фармацевтический препарат, содержащий клодронат в качестве активного ингредиента и агрегат микрокристаллической целлюлозы и диоксида кремния в качестве наполнителя
US20020052367A1 (en) Pharmaceutical compositions containing carvedilol and hydrochlorothiazide
CN1145479C (zh) 药物制剂
US6451343B1 (en) Composition for treating dementia and Alzheimer's disease
RU2199318C2 (ru) Стабилизированные в отношении рацемизации фармацевтические лекарственные формы силанзетрона
CA1334074C (en) Pharmaceutical composition containing high drug load and method for preparing same
AU611740B2 (en) Pharmaceutical composition and process for its preparation
EP0557064B1 (en) Modified release formulation
RU2287328C2 (ru) Твердый препарат с высоким всасыванием
KR102533637B1 (ko) 화합물과 푸마르산의 결정체, 코로나바이러스 유발 질환의 치료를 위한 약학적 조성물 및 방법
WO2007029124A2 (en) Formulations containing pantoprazole free acid and its salts
JP2000219639A (ja) 医薬組成物
MXPA04006977A (es) Composicion farmaceutica que comprende acido 2,2-dicloro-12-(4-clorofenil)-dodecanoico.
NZ270729A (en) Fluvastatin sodium in an alkaline carrier
KR20190076702A (ko) 벤즈이미다졸계 화합물을 포함하는 약제학적 조성물 및 이의 제조방법
HU215191B (hu) Eljárás Levodopa és Carbidopa hatóanyag-kombinációt tartalmazó, szabályozott hatóanyag-leadású, központi dopaminhiányos állapotok kezeléséhez alkalmas orális gyógyszerkészítmény előállítására
HK1069772A (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid
KR20080043904A (ko) 암로디핀 및 그 염을 함유한 필름코팅 제제

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)